image
Healthcare - Biotechnology - NASDAQ - US
$ 46.99
0.0213 %
$ 3.54 B
Market Cap
-13.78
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SWTX stock under the worst case scenario is HIDDEN Compared to the current market price of 47 USD, SpringWorks Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SWTX stock under the base case scenario is HIDDEN Compared to the current market price of 47 USD, SpringWorks Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SWTX stock under the best case scenario is HIDDEN Compared to the current market price of 47 USD, SpringWorks Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SWTX

image
$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
192 M REVENUE
3417.33%
-278 M OPERATING INCOME
18.92%
-258 M NET INCOME
20.60%
-176 M OPERATING CASH FLOW
21.18%
64.5 M INVESTING CASH FLOW
85.72%
4.76 M FINANCING CASH FLOW
-98.39%
49.1 M REVENUE
-20.25%
-80.5 M OPERATING INCOME
0.99%
-83.2 M NET INCOME
-7.62%
-68.8 M OPERATING CASH FLOW
-133.08%
73.4 M INVESTING CASH FLOW
418.86%
-10.6 M FINANCING CASH FLOW
-1624.66%
Balance Sheet SpringWorks Therapeutics, Inc.
image
Current Assets 380 M
Cash & Short-Term Investments 308 M
Receivables 46.2 M
Other Current Assets 26.2 M
Non-Current Assets 207 M
Long-Term Investments 158 M
PP&E 26.7 M
Other Non-Current Assets 22 M
52.44 %7.87 %4.47 %26.92 %4.54 %3.75 %Total Assets$587.3m
Current Liabilities 100 M
Accounts Payable 12.2 M
Short-Term Debt 1.73 M
Other Current Liabilities 86 M
Non-Current Liabilities 6.18 M
Long-Term Debt 6.18 M
Other Non-Current Liabilities 0
11.54 %81.01 %5.82 %Total Liabilities$106.2m
EFFICIENCY
Earnings Waterfall SpringWorks Therapeutics, Inc.
image
Revenue 192 M
Cost Of Revenue 12.6 M
Gross Profit 179 M
Operating Expenses 457 M
Operating Income -278 M
Other Expenses -20 M
Net Income -258 M
200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)192m(13m)179m(457m)(278m)20m(258m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
93.45% GROSS MARGIN
93.45%
-145.17% OPERATING MARGIN
-145.17%
-134.73% NET MARGIN
-134.73%
-53.65% ROE
-53.65%
-43.95% ROA
-43.95%
-56.88% ROIC
-56.88%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis SpringWorks Therapeutics, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -258 M
Depreciation & Amortization 3.47 M
Capital Expenditures -4.45 M
Stock-Based Compensation 109 M
Change in Working Capital -37.9 M
Others 12.7 M
Free Cash Flow -180 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets SpringWorks Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for SWTX of $67 , with forecasts ranging from a low of $47 to a high of $78 .
SWTX Lowest Price Target Wall Street Target
47 USD 0.02%
SWTX Average Price Target Wall Street Target
67 USD 42.58%
SWTX Highest Price Target Wall Street Target
78 USD 65.99%
Price
Max Price Target
Min Price Target
Average Price Target
808075757070656560605555505045454040353530302525Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership SpringWorks Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
25.1 M USD 6
6-9 MONTHS
2.87 M USD 2
9-12 MONTHS
2.8 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion)*, following regulatory clearances and the fulfillment of other customary closing conditions. The definitive agreement between Merck KGaA, Darmstadt, Germany and SpringWorks, based in Stamford, Connecticut, was announced on 28 April, 20. businesswire.com - 6 days ago
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors – If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors – globenewswire.com - 2 weeks ago
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SpringWorks Therapeutics, Inc. (NasdaqGS: SWTX) to Merck KGaA, Darmstadt, Germany. Under the terms of the proposed transaction, shareholders of SpringWorks will receive $47.00 in cash for each share of SpringWorks that they own. KSF is seeking to determine whether this consideration and the pro. businesswire.com - 1 month ago
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025. zacks.com - 1 month ago
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN – If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – globenewswire.com - 1 month ago
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $1.18 per share a year ago. zacks.com - 1 month ago
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SpringWorks Therapeutics, Inc. (NasdaqGS: SWTX) to Merck KGaA, Darmstadt, Germany. Under the terms of the proposed transaction, shareholders of SpringWorks will receive $47.00 in cash for each share of SpringWorks that they own. KSF is seeking to determine whether this consideration and the pro. businesswire.com - 2 months ago
Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in SpringWorks Therapeutics (SWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 2 months ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX NEW YORK , April 28, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating SpringWorks Therapeutics, Inc. (NASDAQ: SWTX ), relating to the proposed merger with Merck KGaA, Darmstadt, Germany. prnewswire.com - 2 months ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc. NEW YORK , April 28, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) and its board of directors concerning the proposed acquisition of the company by Merck KGaA. Stockholders will receive $47.00 for each share of SpringWorks Therapeutics stock that they hold. prnewswire.com - 2 months ago
Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of SpringWorks will receive only $47 per share in cash, which represents an equity value of. businesswire.com - 2 months ago
Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics (SWTX) for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments. investopedia.com - 2 months ago
8. Profile Summary

SpringWorks Therapeutics, Inc. SWTX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 3.54 B
Dividend Yield 0.00%
Description SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Contact 100 Washington Boulevard, Stamford, CT, 06902 https://www.springworkstx.com
IPO Date Sept. 13, 2019
Employees 368
Officers Dr. James Cassidy M.D., Ph.D. Chief Medical Officer Mr. Bhavesh Ashar M.B.A. Chief Commercial Officer Mr. Daniel J. Pichl Chief People Officer Dr. Badreddin Edris Ph.D. Chief Operating Officer Mr. Tai-An Lin Ph.D. Chief Scientific Officer Ms. Kim Diamond Vice President of Communications & Investor Relations Mr. Herschel S. Weinstein J.D. General Counsel & Secretary Mr. Saqib Islam J.D. Chief Executive Officer & Director Mr. Michael P. Nofi Chief Accounting Officer Mr. Francis I. Perier Jr., M.B.A. Chief Financial Officer